Damià is managing partner and co-founder of Columbus Venture Partners. Previously, he founded several biotech companies such as Artax Biopharma Inc, Bioncotech Therapeutics SL, Restaura Biotech SL, or PTS Sl. From 2010 to 2013 he was CEO of Bioncotech Therapeutics, an oncology clinical stage drug development company. Recently, he served as CEO of Artax Biopharma, an autoimmune drug development pharmaceutical company in Cambridge, MA. Damia is currently on the Boards of Viralgen Vector Core, Polypeptide Therapeutic Solutions, Artax Biopharma and Bioncotech Therapeutics. Before this, he was a researcher in different institutions such as the Uniklinik Bonn, University of Michigan or the Spanish National Cancer Center (CNIO). He has been awarded several prizes related to innovation and entrepreneurship, including TR35 from MIT, the Biogen Foundation Award or the Princess Girona Foundation Award.
Damia holds a MSc in Biological Sciences from the University of Valencia,a Master in Biotechnology Managment from IE Business School and earned his PhD in Immunology and Molecular Genetics from the Rheinische Friedrich-Wilhelms-Universität Bonn, Germany